Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is a leading digital therapeutics company, with a vertically integrated health intelligence platform that is driving strong clinical outcomes and sustained engagement. The company's transition to the enterprise end-markets is showing signs of success and is expected to lead to share gains, earnings revision, and multiple expansion. Despite facing challenges with revenue growth and cost management, the company's focus on expanding its pipeline and partnerships, as well as its improving cost structure, make it a strong investment opportunity in the digital health industry.

Bears say

DarioHealth is a virtual chronic care company, founded in 2011, with a recent focus on B2B2C solutions that utilize connected devices, personalized engagement, and digital and human coaching. While the company has seen success in expanding its reach through partnerships and new accounts, currently in the contracting phase with its largest partner to date, its financials show a growing revenue of $25.5 million in 2026 and $40.5 million in 2027, but with a projected adj. EBITDA of ($16.7 million) and ($3 million) respectively, causing a negative outlook for the stock.

DarioHealth (DRIO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 2 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.